Analyst Price Target is $4.85
▲ +112.57% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for InspireMD in the last 3 months. The average price target is $4.85, with a high forecast of $5.20 and a low forecast of $4.50. The average price target represents a 112.57% upside from the last price of $2.28.
Current Consensus is
Buy
The current consensus among 1 investment analysts is to buy stock in InspireMD. This Buy consensus rating has held steady for over two years.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Read More